Maze Therapeutics (MAZE) Institutional Ownership $13.49 +0.26 (+1.97%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Maze Therapeutics (NASDAQ:MAZE)Number ofInstitutional Buyers(last 12 months)35TotalInstitutional Inflows(last 12 months)$280.64MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$3.92M Get MAZE Insider Trade Alerts Want to know when executives and insiders are buying or selling Maze Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MAZE Institutional Buying and Selling by Quarter Maze Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Tower Research Capital LLC TRC 4,608$57K0.0%+452.5%0.011% 8/15/2025 Octagon Capital Advisors LP177,667$2.18M0.5%-62.0%0.405% 8/15/2025 Frazier Life Sciences Management L.P.4,567,275$56.04M2.2%+10.6%10.416% 8/15/2025 Engineers Gate Manager LP10,212$125K0.0%N/A0.023% 8/15/2025 Boothbay Fund Management LLC75,530$927K0.0%-22.1%0.172% 8/15/2025 Bank of America Corp DE5,782$71K0.0%+33.6%0.013% 8/13/2025 Invesco Ltd.18,430$226K0.0%-10.3%0.042% 8/13/2025 CW Advisors LLC30,235$371K0.0%N/A0.069% 8/13/2025 Virtus Investment Advisers LLC6,940$85K0.0%N/A0.016% 8/12/2025 Legal & General Group Plc4,242$52K0.0%+387.0%0.010% Get the Latest News and Ratings for MAZE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/12/2025 JPMorgan Chase & Co.4,366$54K0.0%-56.9%0.010% 8/12/2025 Ensign Peak Advisors Inc18,539$227K0.0%N/A0.042% 8/8/2025 Geode Capital Management LLC231,237$2.84M0.0%+8.8%0.528% 7/25/2025 CWM LLC2,266$28K0.0%N/A0.005% 6/27/2025 Goldman Sachs Group Inc.13,129$145K0.0%N/A0.030% 5/29/2025 Rhumbline Advisers7,235$80K0.0%N/A0.017% 5/16/2025 Woodline Partners LP929,102$10.23M0.1%N/A2.121% 5/16/2025 Octagon Capital Advisors LP468,000$5.15M0.6%N/A1.069% 5/16/2025 Goldman Sachs Group Inc.13,129$145K0.0%N/A0.030% 5/16/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.5,135$57K0.0%N/A0.012% 5/16/2025 ARCH Venture Management LLC4,120,053$45.36M22.0%N/A9.407% 5/16/2025 Alyeska Investment Group L.P.125,000$1.38M0.0%N/A0.285% 5/15/2025 Frazier Life Sciences Management L.P.4,129,001$45.46M2.1%N/A9.428% 5/15/2025 Hhlr Advisors LTD.457,535$5.04M0.1%N/A1.045% 5/15/2025 Ghisallo Capital Management LLC30,000$330K0.0%N/A0.068% 5/15/2025 Driehaus Capital Management LLC132,115$1.46M0.0%N/A0.302% 5/14/2025 Affinity Asset Advisors LLC250,000$2.75M0.3%N/A0.571% 5/14/2025 Corebridge Financial Inc.4,328$48K0.0%N/A0.010% 5/14/2025 Matrix Capital Management Company LP2,486,184$27.37M7.9%N/A5.677% 5/12/2025 Nuveen LLC11,375$125K0.0%N/A0.026% 5/12/2025 Invesco Ltd.20,552$226K0.0%N/A0.047% 5/9/2025 Deutsche Bank AG8,885$98K0.0%N/A0.020% 5/9/2025 TRV GP V LLC950,800$10.47M8.4%N/A2.171% 5/9/2025 TRV GP IV LLC6,073,958$66.87M72.0%N/A13.869% 5/9/2025 Charles Schwab Investment Management Inc.72,305$796K0.0%N/A0.165% 5/9/2025 Harvard Management Co. Inc.637,528$7.02M0.6%N/A1.456% 5/2/2025 Alphabet Inc.2,412,471$26.56M1.7%N/A5.508% 5/1/2025 New York State Common Retirement Fund2,300$25K0.0%N/A0.005% 4/29/2025 Bank of New York Mellon Corp17,233$190K0.0%N/A0.039% 4/23/2025 Bessemer Group Inc.481,790$5.31M0.0%N/A1.100% This stock could leave NVDA in the dust (Ad)Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.Click to get the full details on Eric Fry's "Nvidia alternative" right here.4/16/2025 General Catalyst Group Management LLC1,035,910$11.41M1.3%N/A2.365% (Data available from 1/1/2016 forward) MAZE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MAZE shares? During the previous two years, 37 institutional investors and hedge funds held shares of Maze Therapeutics. The most heavily invested institutionals were TRV GP IV LLC ($66.87M), Frazier Life Sciences Management L.P. ($56.04M), ARCH Venture Management LLC ($45.36M), Matrix Capital Management Company LP ($27.37M), Alphabet Inc. ($26.56M), General Catalyst Group Management LLC ($11.41M), and TRV GP V LLC ($10.47M).Learn more on Maze Therapeutics' institutional investors. Which institutional investors have been buying Maze Therapeutics' stock? Of the 35 institutional investors that purchased Maze Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: TRV GP IV LLC ($6.07M), Frazier Life Sciences Management L.P. ($4.57M), ARCH Venture Management LLC ($4.12M), Matrix Capital Management Company LP ($2.49M), Alphabet Inc. ($2.41M), General Catalyst Group Management LLC ($1.04M), and TRV GP V LLC ($950.80K). How much institutional buying is happening at Maze Therapeutics? Institutional investors have bought a total of 25,428,892 shares in the last 24 months. This purchase volume represents approximately $280.64M in transactions. Which of Maze Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Maze Therapeutics stock in the last 24 months: Octagon Capital Advisors LP ($290.33K), Boothbay Fund Management LLC ($21.44K), JPMorgan Chase & Co. ($5.78K), and Invesco Ltd. ($2.12K). How much institutional selling is happening at Maze Therapeutics? Institutional investors have sold a total of 319,668 shares in the last 24 months. This volume of shares sold represents approximately $3.92M in transactions. Related Companies Centessa Pharmaceuticals Institutional Ownership ImmunityBio Institutional Ownership Belite Bio Institutional Ownership Arrowhead Pharmaceuticals Institutional Ownership Recursion Pharmaceuticals Institutional Ownership Agios Pharmaceuticals Institutional Ownership Ocular Therapeutix Institutional Ownership Bausch Health Cos Institutional Ownership Denali Therapeutics Institutional Ownership Tarsus Pharmaceuticals Institutional Ownership This page (NASDAQ:MAZE) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access